MGC Pharmaceuticals Limited Dispatch of General Meeting Documents (9892A)

TIDMMXC

RNS Number : 9892A

MGC Pharmaceuticals Limited

30 May 2023

MGC Pharmaceuticals Ltd.

Dispatch of General Meeting Documents

30 May 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to advise that it has dispatched the following documentation related to the General Meeting of shareholders to be held at 4:00pm (AWST) on Thursday, 29 June 2023 at 1202 Hay Street, West Perth, Western Australia 6005, to shareholders of the Company.

   1.     Notice of Access, a copy of which can be found at the following URL: 

https://www.investi.com.au/api/announcements/mxc/b164a71f-22f.pdf

   2.     Notice of General Meeting, a copy of which can be found at the following URL: 

https://www.investi.com.au/api/announcements/mxc/fa161f18-4e5.pdf

-Ends-

Authorised for release by the Chairman, for further information please contact:

 
 MGC Pharmaceuticals Ltd                        MGC Pharmaceuticals Ltd 
  Roby Zomer                                     Arron Canicais / Rowan Harland 
  CEO & Managing Director                        Joint Company Secretaries 
  [phone]                                [phone] 
  [e-mail]                           [e-mail] 
 UK Brokers                                     UK Brokers 
  Peterhouse Capital                             Oberon Capital 
  Charles Goodfellow / Lucy Williams             Aimee McCusker / Adam Pollock 
  / Duncan Vasey                                 [phone] 
  [phone]                               [e-mail] 
  [e-mail] / [e-mail]    [e-mail] 
 UK IR/PR Advisers 
  IFC Advisory 
  Graham Herring / Tim Metcalfe / 
  Zach Cohen 
  [phone] 
  [e-mail] 
 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOGWPUAWAUPWUAU

(END) Dow Jones Newswires

May 30, 2023 02:00 ET (06:00 GMT)